{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:42:55Z","timestamp":1773283375756,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.diagmicrobio.2010.12.018","type":"journal-article","created":{"date-parts":[[2011,5,22]],"date-time":"2011-05-22T11:28:19Z","timestamp":1306063699000},"page":"270-273","source":"Crossref","is-referenced-by-count":10,"title":["In vitro activity of tigecycline against extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study"],"prefix":"10.1016","volume":"70","author":[{"given":"Jesus","family":"Silva-Sanchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Reyna-Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma. Elena","family":"Velazquez-Meza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Rojas-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Benitez-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Sanchez-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0005","first-page":"98","article-title":"Methicillin-resistant Staphylococcus aureus at a general hospital: epidemiological overview between 2000\u20132007","volume":"61","author":"Alvarez","year":"2009","journal-title":"Rev. Invest. Clin."},{"issue":"Spec No 1","key":"10.1016\/j.diagmicrobio.2010.12.018_bb0010","first-page":"9","article-title":"New therapeutic options for the treatment of multiresistant bacteria in the ICU","volume":"21","author":"Barcenilla","year":"2008","journal-title":"Rev. Esp. Quimioter."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0015","first-page":"583","article-title":"Tigecycline: in vitro antimicrobial activity in hospitalized patients in an infectology hospital","volume":"47","author":"Barriga-Angulo","year":"2009","journal-title":"Rev. Med. Inst. Mex. Seguro. Soc."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijantimicag.2008.07.031","article-title":"Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)","volume":"33","author":"Bouchillon","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0025","series-title":"Performance standards for antimicrobial susceptibility testing: 20th informational supplement, M100-S20","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2010"},{"issue":"Suppl 5","key":"10.1016\/j.diagmicrobio.2010.12.018_bb0030","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin\u2013aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.diagmicrobio.2009.07.010","article-title":"In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007","volume":"65","author":"Garrison","year":"2009","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000319903","article-title":"Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii","volume":"56","author":"Garza-Gonzalez","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0045","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.coph.2005.04.013","article-title":"Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens","volume":"5","author":"Helfand","year":"2005","journal-title":"Curr. Opin. Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0050","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/archinte.165.12.1375","article-title":"Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: variability by site of infection","volume":"165","author":"Hyle","year":"2005","journal-title":"Arch. Intern. Med"},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","article-title":"Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study","volume":"10","author":"Kumarasamy","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/dki239","article-title":"CTX-M: Changing the face of ESBLs in the UK","volume":"56","author":"Livermore","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.47.1.400-404.2003","article-title":"Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates","volume":"47","author":"Milatovic","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijantimicag.2004.11.006","article-title":"Tigecycline: clinical evidence and formulary positioning","volume":"25","author":"Nathwani","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0075","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1590\/S1413-86702008000500012","article-title":"Rates of antimicrobial resistance in Latin America (2004\u20132007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics","volume":"12","author":"Rossi","year":"2008","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.diagmicrobio.2006.08.016","article-title":"Comparative activities of cefepime and piperacillin\/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype","volume":"57","author":"Sader","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1590\/S1413-86702009000600003","article-title":"Bloodstream factors for multidrug-resistance","volume":"13","author":"Serefhanoglu","year":"2009","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.12.018_bb0095","series-title":"Wyeth","author":"Wyeth Pharmaceuticals Inc (2005). Tygacil product insert Philadelphia, PA","year":"2005"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889310005894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889310005894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T17:23:25Z","timestamp":1543771405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889310005894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0732889310005894"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.12.018","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}